- Rituximab versus cyklofosfamid v ANCA- sociované vaskulitidě.2010 | 1. lékařská fakulta
- Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial2015 | 1. lékařská fakulta
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma2017 | Publikace bez příslušnosti k fakultě
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma2019 | Lékařská fakulta v Hradci Králové
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group2011 | 1. lékařská fakulta
- Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia2015 | Publikace bez příslušnosti k fakultě
- Léčba starších pacientů s lymfomem plášťových buněk2012 | 1. lékařská fakulta
- Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma2020 | 1. lékařská fakulta
- A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma2017 | 1. lékařská fakulta
- Dimethyl fumarate induces ferroptosis and impairs NF-kappa B/STAT3 signaling in DLBCL2021 | 1. lékařská fakulta
- A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL2016 | Lékařská fakulta v Hradci Králové
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma2022 | 1. lékařská fakulta
- Combined Therapeutic Modality with Rituximab, Fludarabin and Cyclophosphamide Followed by High Dose Therapy with Autologous Stem Cell Transplantation (ASCT) Leads to Excellent Response Rate and High Probability of Molecular Remission in Chronic Lymphocytic Leukemia (CLL) PatientsPublikace bez příslušnosti k fakultě
- Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP2020 | 1. lékařská fakulta, 2. lékařská fakulta, 3. lékařská fakulta
- Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy2019 | 1. lékařská fakulta
- A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma2021 | 1. lékařská fakulta
- Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL2019 | 1. lékařská fakulta
- ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma2021 | Lékařská fakulta v Hradci Králové, Ústřední knihovna
- Antibody-Negative Autoimmune Encephalitis: A Single-Center Retrospective Analysis2023 | Ústřední knihovna, 2. lékařská fakulta